Home › Research › Getting a diagnosis
Current understanding of Alzheimer's disease diagnosis and treatment
Weller J, Budson A.. F1000Research, 2018-07-31
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Alzheimer's disease is the most common cause of dementia worldwide, with the prevalence continuing to grow in part because of the aging world population. This neurodegenerative disease process is characterized classically by two hallmark pathologies: β-amyloid plaque deposition and neurofibrillary tangles of hyperphosphorylated tau. Diagnosis is based upon clinical presentation fulfilling several criteria as well as fluid and imaging biomarkers. Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall burden of pathology within the brain. Here, we discuss recent advances in our understanding of the clinical evaluation and treatment of Alzheimer's disease, with updates regarding clinical trials still in progress.
What this study adds
Evidence grade: Low
This is a narrative review. This review states that treatment for Alzheimer's disease is currently aimed at symptoms, not at curing or preventing the disease. It notes that trials are underway that aim to reduce the production and overall burden of Alzheimer's pathology in the brain.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Weller, J., & Budson, A. (2018). Current understanding of Alzheimer's disease diagnosis and treatment. F1000Research. https://doi.org/10.12688/f1000research.14506.1
Vancouver
Weller J, Budson A. Current understanding of Alzheimer's disease diagnosis and treatment. F1000Research. 2018. doi:10.12688/f1000research.14506.1. PMID: 30135715.
BibTeX
@article{weller2018-30135715,
author = {Weller, J. and Budson, A.},
title = {{Current understanding of Alzheimer's disease diagnosis and treatment}},
journal = {F1000Research},
year = {2018},
doi = {10.12688/f1000research.14506.1},
pmid = {30135715},
url = {https://doi.org/10.12688/f1000research.14506.1}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Treatment is currently targeted toward symptomatic therapy, although trials are underway that aim to reduce the production and overall burden of pathology within the brain.
Why it matters
This review states that treatment for Alzheimer's disease is currently aimed at symptoms, not at curing or preventing the disease. It notes that trials are underway that aim to reduce the production and overall burden of Alzheimer's pathology in the brain.
New to this subject? Start with our plain-English guide: Getting a diagnosis →
Study details
- Evidence strengthLow
How this study scored 56/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (F1000Research) |
| Journal's citation record | 2 / 4 | F1000Research: journal h-index 167 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 2 / 5 | 2018 — within 10 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 7 / 7 | Cited 1,082 times (OpenAlex, 2026-10-10) |
| Citations per year | 5 / 5 | 108.2 citations a year over 10 year(s) since 2018 |
| Impact for its field and year | 6 / 6 | Cited 55.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 20 other studies in this library |
| Still being cited | 4 / 4 | Cited 365 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Andrew E. Budson: h-index 72 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | Boston University: institution h-index 1,456 (OpenAlex) |
| Multicenter collaboration | 1 / 3 | OpenAlex lists 3 institution(s) in 1 country |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 30135715) |
| Free to read | 2 / 2 | Free to read |
| Total | 56 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.12688/f1000research.14506.1
- PubMed: 30135715
- Original source →
- Free full text: F1000Research →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 17.
Later studies that cite this one
20 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Getting a diagnosis from nearby years
Also in Getting a diagnosis
141 studies in the library are filed under Getting a diagnosis with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Getting a diagnosis hub.